XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has signed a distribution agreement with TechUnit s.r.o. (Limited). TechUnit is a privately owned company focused on medical product distribution, advertisement and promotion. The agreement outlines parameters for the distribution of XYPHY’s Covid-ID Lab in the Czech Republic as well as plans for similar distribution in Hungary, Slovakia, Ukraine and Russia. XPhyto’s proprietary Covid-ID Lab is a rapid RT-PCR test designed to indicate qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. Covid-ID Lab produces results in a 20-minute PCR run time without prior RNA extraction. The deal also gives TechUnit the right to both distribute and sub-distribute Covid-ID Lab on a nonexclusive basis within the Czech Republic and notes potential for territorial exclusivity based on performance. According to the announcement, XPhyto will provide technical training and product, strategy and marketing support as the company anticipates building a strong strategic relationship with TechUnit. The partners will also evaluate opportunities for distribution in additional European territories. “Execution of the distribution agreement with TechUnit is an important step toward building strong European sales,” said XPhyto Therapeutics managing director of German operations Dr. Thomas Beckert in the press release. “This is an important relationship with excellent potential for additional territorial expansion.”
To view the full press release, visit https://ibn.fm/4anf3
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany. The company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.